Your session is about to expire
Januvia vs Actos
Introduction
For patients with type 2 diabetes, certain medications that influence the body's ability to regulate blood sugar levels can help in managing symptoms and preventing complications. Januvia and Actos are two such drugs that are prescribed for this purpose. They each function through different mechanisms within the body, but both aim to control high blood sugar levels in diabetic patients.
Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor which works by increasing levels of incretin hormones like GLP-1, enhancing insulin secretion and reducing glucagon secretion when glucose concentration is elevated. On the other hand, Actos falls under a class of drugs known as thiazolidinediones (TZDs) and primarily acts by decreasing insulin resistance in peripheral tissues like fat cells and muscles while also inhibiting liver glucose production.
Januvia vs Actos Side By Side
Attribute | Januvia | Actos |
---|---|---|
Brand Name | Januvia | Actos |
Contraindications | History of heart failure, diabetic ketoacidosis | History of heart failure, diabetic ketoacidosis, bladder cancer risk with long-term use |
Cost | Around $470 for 30 tablets of 100 mg | About $240 for 30 tablets of 45 mg |
Generic Name | Sitagliptin | Pioglitazone |
Most Serious Side Effect | Signs of pancreatitis, allergic reactions, kidney problems | Heart failure symptoms, bladder cancer symptoms |
Severe Drug Interactions | Not specifically mentioned in the text | Not specifically mentioned in the text |
Typical Dose | 100 mg/day | 15–45 mg/day |
What is Januvia?
Sitagliptin (the generic name for Januvia) is a well-known drug of the DPP-4 inhibitor class that was introduced as an innovative addition to the medications used to combat type 2 diabetes. Sitagliptin gained FDA approval in 2006. Its operation involves increasing levels of incretin hormones, which helps control blood sugar by increasing insulin release and reducing glucose production. It is often prescribed for adults with type 2 diabetes who struggle to control their blood sugar levels through diet and exercise alone.
In contrast, Pioglitazone (commonly known as Actos), from the thiazolidinedione class, works differently - it makes cells more responsive to insulin, thus reducing the amount of glucose produced by your liver while improving its uptake in muscle cells. While both drugs are effective at managing high blood sugar levels associated with type 2 diabetes, they target different pathways in your body's metabolic process. As such, they may have differing side effects profiles; patients should take care when choosing between them based on individual health status and lifestyle factors.
What conditions is Januvia approved to treat?
Januvia is approved for the treatment of different types of diabetes:
- Type 2 diabetes as a monotherapy or in combination with other antidiabetic medications
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- In combination with insulin (with or without metformin) when diet and exercise plus optimal insulin therapy do not provide adequate glycemic control.
How does Januvia help with these illnesses?
Januvia helps to manage type 2 diabetes by increasing the levels of incretins available. These hormones help control blood sugar by increasing insulin release, especially after a meal, and decreasing the amount of glucose produced and released by the liver. Januvia does this by blocking an enzyme known as DPP-4 that breaks down incretins in the body, allowing their beneficial effects on blood glucose regulation to last longer.
Actos also manages type 2 diabetes but through a different mechanism - it makes cells more sensitive to insulin, which means they can take up and use glucose more effectively from your bloodstream reducing overall glucose levels. It belongs to a class of drugs known as thiazolidinediones (TZDs) which work on improving cellular response to insulin.
Both medications aim at regulating blood sugar levels however each uses a distinct approach: Januvia works primarily on preserving gut hormones that stimulate increased insulin secretion post meals while Actos focuses on enhancing effectiveness of already existing insulin in one's body.
What is Actos?
Actos is a brand name for pioglitazone, which is a thiazolidinedione antidiabetic medication. It works by decreasing insulin resistance in the liver and peripheral body tissues (muscle and fat), thereby enhancing sensitivity to insulin at these sites. Pioglitazone also reduces glucose production in the liver. The drug was approved by the FDA in 1999. Because Actos does not stimulate pancreatic beta cells to produce more insulin, it does not cause excessive blood sugar lowering (hypoglycemia) when used alone — unlike sulfonylureas or meglitinides such as Januvia. Its action mechanism implies that its side effect profile will be different than other diabetes drugs; common side effects include weight gain due to fluid retention, muscle pain, sore throat, tooth problems and headache; however it carries less risk of causing hypoglycemia compared with certain other diabetes medicines like Januvia (sitagliptin). This makes it potentially beneficial for diabetic patients who need additional assistance managing their blood glucose levels but are at high risk of experiencing hypoglycemic episodes.
What conditions is Actos approved to treat?
Actos, also known by its generic name pioglitazone, is approved for the management of:
- Type 2 diabetes mellitus
- It is often used in combination with a healthy diet and regular exercise to improve blood sugar control in adults.
In some cases, it may also be used along with other diabetic medications or insulin.
How does Actos help with these illnesses?
Actos is a type of medication known as a thiazolidinedione, which works to treat type 2 diabetes by increasing the body's sensitivity to insulin, thereby allowing more glucose to be taken up into cells from the bloodstream and lowering blood sugar levels. It operates primarily on peroxisome proliferator-activated receptors (PPARs), particularly PPAR-gamma, in fat tissue throughout the body. This action increases the transcription of a number of insulin-responsive genes involved in controlling glucose and lipid metabolism. Thus, unlike Januvia that functions by inhibiting DPP-4 enzyme and consequently enhancing incretin hormones to regulate blood sugar levels, Actos directly enhances insulin sensitivity. Due to its unique mechanism of action and efficacy profile, it may be prescribed when patients do not respond well or cannot tolerate other typical antidiabetic medications such as metformin or sulfonylureas.
How effective are both Januvia and Actos?
Both sitagliptin (Januvia) and pioglitazone (Actos) have established histories of success in treating patients with type 2 diabetes, but they act on different metabolic pathways and may be prescribed under different circumstances. Sitagliptin was approved by the FDA in 2006, followed by pioglitazone a year later. The effectiveness of these two drugs has been studied extensively; they both exhibit notable efficacy in managing blood sugar levels while maintaining promising safety profiles.
Sitagliptin works as an inhibitor of dipeptidyl peptidase 4 (DPP-4), which enhances the body's ability to lower elevated blood sugar levels. A meta-analysis from 2013 showed that sitagliptin effectively reduces HbA1c levels, a key marker for long-term glucose control, compared to placebo or other oral antidiabetic agents. It is well-tolerated and does not typically lead to weight gain - a common concern among diabetic patients.
Pioglitazone works differently by increasing insulin sensitivity through its action on peroxisome proliferator-activated receptors (PPARs) within fat cells. A review from 2010 indicated that pioglitazone can significantly reduce HbA1c levels compared to placebo or other active comparators like metformin or sulfonylureas, though it may lead to modest weight gain as a side effect.
In summary, both Januvia and Actos are effective treatments for type II diabetes with their unique mechanisms offering flexibility based on individual patient needs and responses.
At what dose is Januvia typically prescribed?
Oral dosages of Januvia for adults typically start at 100 mg/day to treat type 2 diabetes, and studies have shown that this dosage is effective for most people. For patients with kidney issues, the starting dose may be reduced to 50 mg or even 25 mg per day. Actos dosages, on the other hand, range from 15–45 mg/day depending on individual response and tolerance. Children and adolescents should not take these medications as they are not approved for use in this age group. In adult populations using either drug, dosage can be adjusted based on efficacy and tolerability after a few weeks of therapy. The maximum daily dose for Januvia is usually set at 100 mg while it's recommended not to exceed a daily dose of 45mg for Actos.
At what dose is Actos typically prescribed?
Actos treatment is typically initiated at a dosage of 15–30 mg/day, taken once daily. The dose can then be increased to a maximum of 45 mg/day based on the patient's glycemic response and tolerance level. It should be noted that Actos is meant to be used as part of an overall diabetes management plan that includes diet and exercise. Therefore, if there is no sufficient reduction in HbA1c levels after several weeks, options may include either increasing the Actos dose or considering combination therapy with another antidiabetic medication.
What are the most common side effects for Januvia?
Common side effects of Januvia include:
- Upper respiratory tract infection
- Stuffy or runny nose and sore throat
- Headache
- Nausea, stomach upset, diarrhea
- Skin rash
- Hypoglycemia (low blood sugar) in combination with other diabetes medications
On the other hand, Actos may cause:
- Weight gain
- Fluid retention causing swelling (edema)
- Anemia
- Upper respiratory tract infections
- Sinusitis
- Muscle pain
Are there any potential serious side effects for Januvia?
While both Januvia and Actos are used to manage blood sugar levels in people with type 2 diabetes, they can potentially cause different side effects. For Januvia, one should be aware of the following:
- Signs of pancreatitis: severe pain in your upper stomach spreading to your back, nausea and vomiting, loss of appetite
- Allergic reactions such as skin rash, hives or itching; redness or swelling of the face/neck/throat; wheezing; trouble breathing
- Kidney problems - little or no urination; painful or difficult urination; swelling in your feet or ankles
For Actos you need to look out for symptoms indicating heart failure:
- Shortness of breath (even while lying down), fatigue and weight gain from water retention.
- Symptoms that indicate bladder cancer: blood in urine, persistent urge to urinate, pelvic pain
Remember that these are not exhaustive lists. If you experience any unusual signs after starting either medication please seek medical attention immediately.
What are the most common side effects for Actos?
Common side effects of Actos may include:
- Edema (fluid retention)
- Weight gain
- Mild anemia
- Headache, muscle pain
- Sinusitis and pharyngitis (sinus and throat infections)
- Upper respiratory tract infection It's important to note that while these are some of the possible side effects, not everyone who takes Actos will experience them. Additionally, serious adverse events such as bladder cancer have been associated with prolonged use of this medication. Always consult your healthcare provider for a thorough understanding of the potential risks and benefits before starting any new treatment.
Are there any potential serious side effects for Actos?
Actos, while generally well-tolerated, can have serious side effects in some instances. If you notice any of the following symptoms while taking Actos, seek medical attention immediately:
- Signs of an allergic reaction: hives; difficulty breathing or swallowing; swelling of your face, lips, tongue, or throat
- Symptoms suggestive of heart failure: shortness of breath (even with mild exertion), swelling or rapid weight gain
- Changes in vision and/or blurred vision
- Blood sugar levels that are too high (hyperglycemia) or too low (hypoglycemia)
- Stomach pain followed by vomiting and loss of appetite - this could be indicative of a liver problem
- Painful urination which might be accompanied by cloudier than usual urine - this could signify a bladder infection.
Remember to always consult with your healthcare provider if you experience these symptoms when using Actos.
Contraindications for Januvia and Actos?
Both Januvia and Actos, as with most diabetes medications, may cause some side effects in certain individuals. If you notice any serious adverse reactions such as severe stomach/abdominal pain that doesn't go away, unusual tiredness or trouble breathing, please seek immediate medical attention.
Neither Januvia nor Actos should be taken if you have a history of heart failure or if your body is in a state of diabetic ketoacidosis (high ketones and acid levels in your blood or urine). Always inform your healthcare provider about all the medications and supplements you are taking; this includes over-the-counter medicines and herbal products.
Actos requires special caution because it's known to increase the risk of bladder cancer when used for more than one year. Also, both drugs can lower blood sugar too much especially when combined with other forms of diabetes medication. It's therefore important to carefully monitor your blood sugar levels regularly while on these drugs.
How much do Januvia and Actos cost?
For the brand-name versions of these antidiabetic medications:
- The price for 30 tablets of Januvia (100 mg) averages around $470, which works out to approximately $15.70/day.
- The cost for 30 tablets of Actos (45 mg) is about $240, working out to roughly $8/day.
Thus, if you are on a daily regimen, Actos is less expensive than Januvia on a per-day treatment basis. However, it's crucial to remember that cost shouldn't be your primary consideration when deciding between these two medications.
In terms of their generic versions:
- Sitagliptin (the generic version of Januvia) can range in price from about $14 - $20 per tablet or around $420 - $600 per month.
- Pioglitazone (generic Actos), conversely, costs considerably less at an average price ranging between only about a dollar to three dollars per pill or roughly between from as low as ~$25 up to ~$90/month depending upon dosage and quantity purchased.
As always with any medication decision, both efficacy and personal tolerance should be considered alongside cost.
Popularity of Januvia and Actos
Sitagliptin, in generic form as well as brand names such as Januvia, was estimated to have been prescribed to about 10.5 million people in the US in 2020. Sitagliptin accounted for just over 8% of prescriptions for anti-diabetic medication in the US. However, it appears to be one of the most commonly used medications within its class, known as DPP-4 inhibitors.
Pioglitazone, including brand versions such as Actos, was prescribed to around 3 million people in the USA during that same period. In the United States market for diabetes medicines, pioglitazone accounts for approximately 2% of all prescriptions and is a member of a different drug class called thiazolidinediones or TZDs. The prevalence of pioglitazone has been declining gradually due mainly to concerns regarding side effects and introduction of newer treatment options.
Conclusion
Both Januvia (sitagliptin) and Actos (pioglitazone) are well-established in the management of type 2 diabetes, with numerous clinical studies indicating their efficacy over placebo treatments. In some cases, these medications may be used together but this is subject to careful consideration by a physician as they do have differing mechanisms of action. Januvia acts primarily by inhibiting DPP-4 enzyme which promotes the release of insulin, whereas Actos works mainly by increasing the sensitivity of cells to insulin.
Januvia is often considered a first-line treatment option due to its lower risk profile for weight gain and heart failure compared to Actos, which would typically be added on or chosen when patients cannot tolerate other first-line drugs such as metformin or sulfonylureas.
Both medicines are available in generic form representing significant cost savings especially for patients who must pay out-of-pocket. Both Januvia and Actos may require an adjustment period, meaning that effects might not be noticeable right away.
The side effect profiles between these two drugs vary somewhat; both being generally well-tolerated but with important differences. For instance, while Januvia has been associated with pancreatitis and joint pain in rare cases, use of Actos can lead to weight gain and carries a higher risk for heart failure and bone fractures. It's crucial for patients using either drug to monitor their blood sugar levels regularly and should seek medical help immediately if they notice symptoms like severe stomach pain or unusual bruising.
Refrences
- Gadsby, R. (2007, December). New treatments for type 2 diabetes—The DPP4 inhibitors. Primary Care Diabetes. Elsevier BV.http://doi.org/10.1016/j.pcd.2007.10.004
- Dhillon, S. (2010, March). Sitagliptin. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/11203790-000000000-00000
- Vilsbøll, T. (2008, January). Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus. Expert Review of Endocrinology & Metabolism. Informa UK Limited.http://doi.org/10.1586/17446651.3.1.13
- Bardsley, J. K., & Ratner, R. E. (2008, November). Sitagliptin: an oral agent for glucose control. Expert Review of Endocrinology & Metabolism. Informa UK Limited.http://doi.org/10.1586/17446651.3.6.691
- Scott, L. J. (2017, January 11). Sitagliptin: A Review in Type 2 Diabetes. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-016-0686-9
- Reynolds, J. K., Neumiller, J. J., & Campbell, R. K. (2008, September 22). Janumet<sup>™</sup>: a combination product suitable for use in patients with Type 2 diabetes. Expert Opinion on Investigational Drugs. Informa Healthcare.http://doi.org/10.1517/13543784.17.10.1559
- Waugh, J., Keating, G. M., Plosker, G. L., Easthope, S., & Robinson, D. M. (2006). Spotlight on Pioglitazone in Type 2 Diabetes Mellitus1. Treatments in Endocrinology. Springer Science and Business Media LLC.http://doi.org/10.2165/00024677-200605030-00006